MedTrace Logo

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

NCT05930925 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-09-13

No results posted yet for this study

Summary

The purpose of the study is to understand how the study medicine ARV-471 is processed in the body of healthy males and females who do not have the potential to have children.

This study is seeking for participants who:

* are healthy males and females who do not have the potential to have children.
* are 18 years of age or older.
* weigh more than 110 pounds.

Conditions

  • Healthy

Interventions

DRUG

[phenyl-14C]ARV-471

Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth

DRUG

[oxoisoindolin-14C]ARV-471

Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth

Sponsors & Collaborators

  • Arvinas Estrogen Receptor, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-12
Primary Completion
2023-07-27
Completion
2023-08-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05930925 on ClinicalTrials.gov